Approval Background

Zercepac is a trastuzumab biosimilar that received approval from the European Medicines Agency (EMA) on July 27, 2020. The reference trastuzumab is a cornerstone therapy for HER2‑positive breast cancer, and there has been a strong demand for cost reduction and broader patient access. The EMA reviewed clinical data and manufacturing quality and recognized equivalent efficacy and safety.

Clinical Evidence

Zercepac demonstrated comparable anticancer efficacy and safety profile to the reference product in a randomized, double‑blind, comparative clinical trial. No statistically significant differences were observed in progression‑free survival (PFS) or overall survival (OS). These results reinforce the scientific basis that the biosimilar provides the same therapeutic benefit as the originator.

Positioning Relative to Competitors

Zercepac offers price competitiveness while maintaining the same quality as the reference product. EMA approval accelerates market entry and is expected to drive pricing pressure and expanded reimbursement. As competition among biosimilars intensifies, the availability of innovative therapies is likely to increase.

Reimbursement and Market Entry Constraints

Post‑approval patient access may vary depending on reimbursement policies of individual health authorities. Some countries may apply reimbursement conditions identical to the reference product, while others could establish differentiated reimbursement levels during price negotiations. Prescribing habits of clinicians and patient perceptions will also influence market penetration. Initial market share is expected to grow gradually.